| Released | Contributor | Author | Title | Pages | Price |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| SLXP has a current Overall Rating of C (Neutral). | 7 |
$25 |
| 25-Nov-2009 | New Constructs, LLC |
N/A
| SLXP: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 25-Nov-2009 | Pechala's Reports | Lubomir Pechala | SALIX PHARMACEUTICALS LTD (SLXP=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 24-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 23-Nov-2009 | PriceTarget Research, Inc. |
N/A
| S&P Small Cap Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$40 |
| 23-Nov-2009 | PriceTarget Research, Inc. |
N/A
| S&P Super 1500 Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$40 |
| 23-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$20 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) | 71 |
$199 |
| 23-Nov-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 | 569 |
$299 |
| 23-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for SLXP | 13 |
$25 |
0.28% Nasdaq 
0.29 (1.23%) 
Research Reports
